REINVENTING HOW HEALTHCARE PROFESSIONALS AND PATIENTS MANAGE PAIN
Virpax Pharmaceuticals is committed to developing non-addictive product candidates that manage pain and its complexities, while minimizing risks to patients and society. Our proprietary delivery systems will reinvent how patients and prescribers manage pain worldwide.
Pain is a universal condition, while the perception of pain is unique. We are dedicated to creating novel non-addictive treatment options for the management of pain. By combining selected drug compounds with our cutting-edge delivery systems, we strive to maximize our products’ capabilities and successfully bring them to market.
NON-ADDICTIVE PRODUCTS
We are developing numerous drug development strategies that will address the rising need for alternatives to addictive opioid prescription medications. Our robust pipeline harnesses the improved characteristics of the Molecular Envelope Technology (MET), the topical spray film, and the liposomal hydrogel drug-delivery technologies to target pain at its source.
CNS GROWTH OPPORTUNITIES
Our MET platform is being used to grow our Central Nervous System (CNS) disorder pipeline. These additional patented formulations include neurotransmission and neuroprotective actives. The current product candidates include Post Traumatic Stress Disorder (PTSD), and epilepsy in children (Rare Pediatric Disease) and adults. In the future, the MET will be used to deliver actives that will be developed to manage other neurodegenerative disorders.
“Biopharma companies have a deep understanding of the R&D of novel products, making the industry essential to the advancement of public health initiatives.”
ANTHONY P. MACK
CEO of Virpax Pharmaceuticals
We are developing novel drug delivery technologies and we are continuously strengthening our worldwide patents in the development of non-addictive treatments for pain and degenerative neurological disorders.
